Superior Survival With Sintilimab in Squamous NSCLC Superior Survival With Sintilimab in Squamous NSCLC

Second-line treatment with sintilimab improved survival compared with docetaxel in patients with advanced/metastatic squamous nonsmall cell lung cancer in the phase 3 ORIENT-3 trial.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news